Revlimid and Nail infection - a phase IV clinical study of FDA data

Summary:

Nail infection is found among people who take Revlimid, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Revlimid and have Nail infection. It is created by eHealthMe based on reports of 281,221 people who have side effects when taking Revlimid from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.

On May, 22, 2022

281,221 people reported to have side effects when taking Revlimid.
Among them, 12 people (0.0%) have Nail infection.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 281,511 Revlimid users for its effectiveness, alternative drugs and more.

What is Nail infection?

Nail infection is found to be associated with 831 drugs and 424 conditions by eHealthMe.

Number of Revlimid and Nail infection reports submitted per year:

Time on Revlimid when people have Nail infection *:

Gender of people who have Nail infection when taking Revlimid *:

female: 58.33 %
male: 41.67 %

Age of people who have Nail infection when taking Revlimid *:

Common drugs people take besides Revlimid *:

Common side effects people have besides Nail infection *:

Hypotension (abnormally low blood pressure): 2 people, 16.67%
Red Blood Cell Count Decreased: 2 people, 16.67%
Urinary Tract Infection: 2 people, 16.67%
White Blood Cell Count Decreased: 1 person, 8.33%
Blood Magnesium Decreased: 1 person, 8.33%
Blood Potassium Decreased: 1 person, 8.33%
Cellulitis (infection under the skin): 1 person, 8.33%
Fatigue (feeling of tiredness): 1 person, 8.33%
Full Blood Count Decreased: 1 person, 8.33%
Gastrointestinal Infection (infection of stomach and intestine): 1 person, 8.33%

Common conditions people have *:

Hypotension (abnormally low blood pressure): 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Revlimid and have Nail infection?

Check whether Nail infection is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of Revlimid:

Revlimid (281,511 reports)

Nail infection treatments and more:

Nail infection (1,789 reports)

COVID vaccines that are related to Nail infection:

How severe was Nail infection and when was it recovered:

Nail infection in Revlimid

Expand to all the drugs that have ingredients of lenalidomide:

Nail infection and drugs with ingredients of lenalidomide

Common drugs associated with Nail infection:

Enbrel: 142 reports
Humira: 114 reports
Methotrexate: 145 reports
Prednisone: 109 reports

All the drugs that are associated with Nail infection:

Nail infection (831 drugs)

Common conditions associated with Nail infection:

Ra: 287 reports
Rheumatoid arthritis: 287 reports

All the conditions that are associated with Nail infection:

Nail infection (424 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lenalidomide (the active ingredients of Revlimid) and Revlimid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.